Electrochemotherapy in the treatment of neoplasms in dogs and cats

Rangel, Marcelo Monte Mór; Luz, Jean Carlos Dos Santos da; Oliveira, Krishna Düro de; Ojeda, Javier; Freytag, Jennifer; Suzuki, Daniela Ota Hisayasu

doi:10.4067/s0719-81322019000200045

Cited by 14 publications

(11 citation statements)

References 38 publications

(55 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Euthanasia was the main cause of death during the course of this study, representing 77.6% (52) of the deceased patients, where 49.3% (33) of those euthanasias were performed due to local progression and 28.4% (19) due to metastatic progression of the disease. Unrelated causes of death reached 17.9% (12) and finally, 3% (2) of the overall enrolled patients remained alive by the end of the follow-up period (24 months).…”

Section: Cause Of Deathmentioning

confidence: 99%

“…17 In veterinary medicine, ECT is a well-established therapy with multiple indications and proven efficacy. 18,19 It has been reported very good results for treating mast-cell tumors (OR 62.3-100%) [20][21][22] , sarcomas (OR 90%) 23 , perianal tumors (OR 94%) 24 , nasal duct tumors (OR 91%) 24,25 , among others, with minimum to absent side effects.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Electrochemotherapy in treatment of canine oral malignant melanoma and factors influencing treatment outcome

Tellado

Maglietti

Michinski

et al. 2020

Radiology and Oncology

View full text Add to dashboard Cite

BackgroundOral malignant melanoma is the most common, but aggressive oral cancer in dogs with poor prognosis. Electrochemotherapy (ECT) has therapeutic potential in such tumors as effective local treatment. Therefore, the aim of this prospective clinical study was to evaluate treatment effectiveness of ECT in as first line treatment for canine oral malignant melanoma, and search for factors influencing treatment outcome.MethodsSixty-seven canines with primary oral malignant melanoma, non-candidates for first-line therapy, were enrolled. All dogs received ECT and follow-up exams for the span of two years.ResultsBased on RECIST criteria, the objective response rate was 100%, 89.5%, 57.7%, and 36.4%, in stage I, II, III and IV, respectively. Only patients in stage I, II and III with partial or complete response improved their quality of life. The median time to progression was 11, 7, 4 and 4 months, and median survival time after the treatment was 16.5, 9.0, 7.5 and 4.5 months, for patients in stage I, II, III and IV, respectively. Significantly better was local response in stage I and II disease (p = 0.0013), without the bone involvement (p = 0.043)ConclusionsElectrochemotherapy is effective local treatment of oral canine malignant melanoma when no alternative treatment is available. Better response is expected in stage I and II patients with tumors without bone involvement.

show abstract

Section: Cause Of Deathmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Electrochemotherapy in treatment of canine oral malignant melanoma and factors influencing treatment outcome

Tellado

Maglietti

Michinski

et al. 2020

Radiology and Oncology

View full text Add to dashboard Cite

show abstract

“…In particular, the group of Dr. Marshall made several publications on this topic [ 10 , 70 , 97 , 102 , 103 , 104 , 105 , 106 , 107 , 108 ]. The use of ECT in veterinary medicine began in 2008 in Brazil by the group of Dr. Rangel [ 109 , 110 , 111 , 112 , 113 , 114 ], closely followed by the group of Dr. Marshall, from Argentina, in 2009. Although the treatment had been used in human medicine in Europe since 2006, there were no devices available in Latin America for human nor veterinary medicine at that time.…”

Section: State Of the Art Of Electroporation-based Treatments In Lmentioning

confidence: 99%

Electroporation as the Immunotherapy Strategy for Cancer in Veterinary Medicine: State of the Art in Latin America

Maglietti

Tellado²,

Robertis

et al. 2020

Vaccines

View full text Add to dashboard Cite

Electroporation is a technology that increases cell membrane permeability by the application of electric pulses. Electrochemotherapy (ECT), the best-known application of electroporation, is a very effective local treatment for tumors of any histology in human and veterinary medicine. It induces a local yet robust immune response that is responsible for its high effectiveness. Gene electrotransfer (GET), used in research to produce a systemic immune response against cancer, is another electroporation-based treatment that is very appealing for its effectiveness, low cost, and simplicity. In this review, we present the immune effect of electroporation-based treatments and analyze the results of the vast majority of the published papers related to immune response enhancement by gene electrotransfer in companion animals with spontaneous tumors. In addition, we present a brief history of the initial steps and the state of the art of the electroporation-based treatments in Latin America. They have the potential to become an essential form of immunotherapy in the region. This review gives insight into the subject and helps to choose promising research lines for future work; it also helps to select the adequate treatment parameters for performing a successful application of this technology.

show abstract

“…This paper investigates electrochemotherapy (ECT), which was first described in 1991 and has shown encouraging results in veterinary oncology [ 22 , 23 ]. This treatment combines the use of reversible electroporation (short high-voltage electric pulses) with cytotoxic drugs [ 9 , 24 ].…”

Section: Introductionmentioning

confidence: 99%

A Retrospective Multicentric Study of Electrochemotherapy in the Treatment of Feline Nasal Planum Squamous Cell Carcinoma

Simčič

Pierini

Lubas

et al. 2021

Veterinary Sciences

View full text Add to dashboard Cite

Feline squamous cell carcinoma (SCC) is currently treated with surgery, radiation therapy and electrochemotherapy (ECT). Both the efficacy and/or safety of ECT were evaluated as a sole therapy with bleomycin to treat feline nasal planum SCC (npSCC). Sixty-one cats were enrolled. Local treatment response was evaluated as complete remission (CR), partial remission (PR) or stable disease (SD). Recurrence rate (RR), disease-free interval (DFI) and progression free survival (PFS) were calculated. A six-point scale was used for ECT toxicity. The median tumor size was 1.5 cm. CR was achieved in 65.6% of cases, PR in 31.1% and SD in 3.3%. The overall response rate was 96.7%, RR was 22.5%, median DFI was 136 days, and median PFS was 65.5 days. ECT toxicity was ≤2 in 51% of cats. Tumor recurrence/progression (p = 0.014) and local treatment response (PR: p < 0.001; SD: p < 0.001) influenced survival time. Cats with toxicity >2 showed a higher probability of tumor recurrence/progression. Tumor-related death was higher in cats with PR (p < 0.001) and recurrence/progression (p = 0.002), in ECT treatment with 1 Hz (p = 0.035) and 1200 V/cm (p = 0.011) or 1300 V/cm (p = 0.016). Tumor size influenced local treatment response (p = 0.008) and toxicity (p < 0.001). ECT is an effective treatment for feline npSCCs and should be considered as the first-line procedure for low-stage tumors.

show abstract

Electrochemotherapy in the treatment of neoplasms in dogs and cats

Cited by 14 publications

References 38 publications

Electrochemotherapy in treatment of canine oral malignant melanoma and factors influencing treatment outcome

Electrochemotherapy in treatment of canine oral malignant melanoma and factors influencing treatment outcome

Electroporation as the Immunotherapy Strategy for Cancer in Veterinary Medicine: State of the Art in Latin America

A Retrospective Multicentric Study of Electrochemotherapy in the Treatment of Feline Nasal Planum Squamous Cell Carcinoma

Contact Info

Product

Resources

About